BIO vs RJF · rev $651.0M vs rev $15.91B
BIO (BIO) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
RJF (RJF) common stock.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
BIO currently screens at market cap $0. RJF currently screens at market cap $0.
Not investment advice. Open the BIO and RJF stock pages for the full models.
Not investment advice.